PE Tech Report


Like this article?

Sign up to our free newsletter

Cresset secures significant growth funding from SEP

Cresset, a UK-based developer of drug discovery and design software, has secured a significant investment from Scottish Equity Partners (SEP), a technology focused growth equity firm. 

With this investment, Cresset will accelerate its drive for exceptional talent to continue broadening the science platform. Additionally, the funding will be used to expand operations internationally, particularly in the US.

Cresset’s computational methods enable its customers to accelerate drug discovery workflows by predicting molecular interactions and enabling prioritisation of drug candidates. Its computer-aided drug discovery (CADD) solutions are used by research chemists globally, including in 8 of the top 10 pharma companies.

Cresset’s specialism is describing molecules using in silico techniques. The company’s software is used by chemists throughout the entire drug discovery pipeline, from virtual screening and hit discovery to lead optimisation and QSAR analysis.

Cresset has significantly accelerated its growth rate in recent years by broadening its core product offering to include both structure and ligand-based design capabilities (via Flare™), and the release of a new comprehensive DMTA workflow suite (via Torx®). Torx enables multiple stakeholders in the drug discovery workflow to make better design decisions and track compound synthesis. 

Like this article? Sign up to our free newsletter